Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Huihui Tang, Ricardo De Matos Simoes, Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Eleni Anastasakou, Oliver Bohorquez, Shizuka Yamano, Evangelos Papadopoulos, Lisa Leypoldt, Arun Wiita, Olwyn Mahon, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2173.

https://doi.org/10.1182/blood-2025-2173

Published: 2025

Journal Articles

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Olga Dashevsky, Ricardo De Matos Simoes, Huihui Tang, Torsten Steinbrunn, Shizuka Yamano, Eleni Anastasakou, Benjamin Barwick, Sara Gandolfi, Ryosuke Shirasaki, Vikas Gupta, Michal Sheffer, Jonathan Licht, Lawrence Boise, Matthew Oser, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 688.

https://doi.org/10.1182/blood-2025-688

Published: 2025

Journal Articles

Integrative genomic, single-cell, and functional profiling uncovers immune consequences of the CD48–CD244 axis in NK cells in multiple myeloma

Bonell Patino-Escobar, Torsten Steinbrunn, Lucy Perez-Lugo, Sham Rampersaud, Huimin Geng, Fernando Salangsang, Paul Phojanakong, Juan Camara-Serrano, Yan Zeng, Veronica Steri, Oscar Aguilar, Constantine Mitsiades, Arun Wiita

Blood (2025) 146 (Supplement 1): 687.

https://doi.org/10.1182/blood-2025-687

Published: 2025

Journal Articles

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Blood (2025) 146 (Supplement 1): 7465.

https://doi.org/10.1182/blood-2025-7465

Published: 2025

Journal Articles

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Blood (2025) 146 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2025-3543

Published: 2025

Journal Articles

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Torsten Steinbrunn, Arnold Bolomsky, Ryosuke Shirasaki, Omar Al-Odat, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Oliver Bohorquez, Brian Glassner, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Ricardo De Matos Simoes, James Christensen, Ryan Young, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 327.

https://doi.org/10.1182/blood-2025-327

Published: 2025

Journal Articles

Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma

Blood (2025) 146 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2025-2152

Published: 2025

Journal Articles

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Blood (2025) 146 (Supplement 1): 802.

https://doi.org/10.1182/blood-2025-802

Published: 2025

Journal Articles

Elevated NQO1 expression mediates proteasome inhibitor resistance and predicts adverse outcomes in multiple myeloma

Blood (2025) 146 (Supplement 1): 6812.

https://doi.org/10.1182/blood-2025-6812

Published: 2025

Journal Articles

Functional Genomics Studies Decipher the Genetic Perturbations and Unravel Mechanisms of Response/Resistance upon Mutant-Specific KRAS Inhibition in Multiple Myeloma

Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Phaik Ju Teoh, Lisa Leypoldt, Brian Glassner, Ricardo De Matos Simoes, James Christensen, Constantine S Mitsiades

Blood (2024) 144 (Supplement 1): 3286.

https://doi.org/10.1182/blood-2024-211598

Published: 2024

Journal Articles

Functional Characterization of Genes Residing in Chromosomal Regions with “High-Risk” Lesions in Multiple Myeloma

Phaik Ju Teoh, Ricardo De Matos Simoes, Tae-Hoon Chung, Torsten Steinbrunn, Lisa B Leypoldt, Olga Dashevsky, Francisca Vazquez, Wee-Joo Chng, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 3293.

https://doi.org/10.1182/blood-2023-190050

Published: 2023

Journal Articles

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Rin Mizuno, Takeru Sugihara, Phaik Ju Teoh, Lisa B Leypoldt, Mariko Kaji, Jeffrey Sorrell, Brian J Glassner, Ricardo De Matos Simoes, James Christensen, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2023-182476

Published: 2023

Journal Articles

Platelet Subpopulations and Distinct Platelet Function Defects after Hematopoietic Stem Cell Transplantation in Mice and Humans

Kristina Mott, Lukas Johannes Weiss, Margret Droste, Maria Drayss, Sabrina Kraus, Torsten Steinbrunn, Harald Schulze

Blood (2023) 142 (Supplement 1): 348.

https://doi.org/10.1182/blood-2023-180641

Published: 2023

Journal Articles

Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments

Lisa B Leypoldt, Torsten Steinbrunn, Phaik Ju Teoh, Ricardo De Matos Simoes, Ryosuke Shirasaki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 3321.

https://doi.org/10.1182/blood-2023-180033

Published: 2023

Journal Articles

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Pooja Shah, Thorsten Stuehmer, Larissa Haertle, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Martin Kortuem, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2022) 140 (Supplement 1): 7076–7077.

https://doi.org/10.1182/blood-2022-166283

Published: 2022

Journal Articles

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Pooja Shah, Thorsten Stuehmer, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2021) 138 (Supplement 1): 1587.

https://doi.org/10.1182/blood-2021-153741

Published: 2021

Journal Articles

Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival

Blood (2019) 134 (Supplement_1): 855.

https://doi.org/10.1182/blood-2019-126674

Published: 2019

Journal Articles

Focusing PI and IMiD Resistance in Multiple Myeloma: Impact of DNA Methylation

Larissa Haertle, PhD, Max Bittrich, MD, Ramya Potabattula, PhD, Matteo Claudio Da Via', MD, Umair Munawar, MS, BS, Yanira Ruiz-Heredia, Cornelia Vogt, Torsten Steinbrunn, Andoni Garitano-Trojaola, PhD, Thorsten Stuehmer, Joaquin Martinez Lopez, MD PhD, Hermann Einsele, MD, Thomas Haaf, MD PhD, K. Martin Kortüm, MD, Santiago Barrio Garcia, PhD

Blood (2018) 132 (Supplement 1): 404.

https://doi.org/10.1182/blood-2018-99-118944

Published: 2018

Journal Articles

Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival.

Marcel Seibold, Thorsten Stuehmer, Anja Mottok, Claus J Scholz, Manik Chatterjee, Ellen Leich, Martin Kortüm, Andreas Schlosser, Hermann Einsele, Andreas Rosenwald, Ralf C Bargou, Torsten Steinbrunn

Blood (2018) 132 (Supplement 1): 3217.

https://doi.org/10.1182/blood-2018-99-119804

Published: 2018

Journal Articles

RAL Mediates Multiple Myeloma Cell Survival Independently of Oncogenic RAS

Marcel Seibold, Thorsten Stuehmer, Nadine Kremer, Anja Mottok, MD PhD, Claus J Scholz, Daniela Bruennert, Manik Chatterjee, Ellen Leich, Andreas Schlosser, Andreas Rosenwald, Hermann Einsele, Ralf C Bargou, Torsten Steinbrunn

Blood (2017) 130 (Supplement 1): 4406.

https://doi.org/10.1182/blood.V130.Suppl_1.4406.4406

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Integrative genomic, single-cell, and functional profiling uncovers immune consequences of the CD48–CD244 axis in NK cells in multiple myeloma

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Elevated NQO1 expression mediates proteasome inhibitor resistance and predicts adverse outcomes in multiple myeloma

Functional Genomics Studies Decipher the Genetic Perturbations and Unravel Mechanisms of Response/Resistance upon Mutant-Specific KRAS Inhibition in Multiple Myeloma

Functional Characterization of Genes Residing in Chromosomal Regions with “High-Risk” Lesions in Multiple Myeloma

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Platelet Subpopulations and Distinct Platelet Function Defects after Hematopoietic Stem Cell Transplantation in Mice and Humans

Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival

Focusing PI and IMiD Resistance in Multiple Myeloma: Impact of DNA Methylation

Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival.

RAL Mediates Multiple Myeloma Cell Survival Independently of Oncogenic RAS

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only